期刊文献+

Development and Validation of UV Spectrophotometric Method to Study Stress Degradation Behaviour of Rizatriptan Benzoate

Development and Validation of UV Spectrophotometric Method to Study Stress Degradation Behaviour of Rizatriptan Benzoate
下载PDF
导出
摘要 Rizatriptan benzoate is a 5HT 1B/1Dreceptor agonist which is prescribed for the treatment of migraine.In the present study new,simple,specific ultraviolet spectrophotometric method for rizatriptan benzoate was developed and validated.Forced degradation studies were carried out in acidic,alkaline and neutral pH conditions.The absorbance maxima peak was found to be 224 nm and linearity was observed in the concentration range of 0.5~2.5μg·mL-1 with regression coefficient value of 0.998 8.The method was validated and found to be precise.The percent recovery for rizatriptan benzoate was found to be 98.576±0.202.The bulk drug was found to be stable in neutral and acidic pH conditions but got degraded in 1N NaOH solution. Rizatriptan benzoate is a 5HT 1B/1Dreceptor agonist which is prescribed for the treatment of migraine.In the present study new,simple,specific ultraviolet spectrophotometric method for rizatriptan benzoate was developed and validated.Forced degradation studies were carried out in acidic,alkaline and neutral pH conditions.The absorbance maxima peak was found to be 224 nm and linearity was observed in the concentration range of 0.5~2.5μg·mL^-1 with regression coefficient value of 0.998 8.The method was validated and found to be precise.The percent recovery for rizatriptan benzoate was found to be 98.576±0.202.The bulk drug was found to be stable in neutral and acidic pH conditions but got degraded in 1N NaOH solution.
出处 《光谱学与光谱分析》 SCIE EI CAS CSCD 北大核心 2015年第1期137-140,共4页 Spectroscopy and Spectral Analysis
关键词 RIZATRIPTAN BENZOATE UV SPECTROSCOPY Stress DEGRADATION VALIDATION Rizatriptan benzoate;UV spectroscopy;Stress degradation;Validation
  • 相关文献

参考文献8

  • 1Chen J, Jiang X G, Jiang W M, et al. Pharmazie, 2005, 60(1): 39.
  • 2Amoozegar F, Pringsheim T. Patient Preference and Adherence, 2009,3: 251.
  • 3Jiang X, Chen J, Jiang W, et al. Journal of Chromatography B, 2004, 805: 169.
  • 4Shyamsundar B, Suneetha A. Ind. J. Pharm. Sci., 2010, 72(6): 798.
  • 5Basavaiah K, Prashanth K N. Journal of Saudi Chemical Society, Article in Press,2013.
  • 6Mallikarjuna B, Sangaraju S, Madhavan P,et al. J. Pharm. and Biomedical. Analysis, 2006, 41: 1146.
  • 7Jagtap S S, Gopu C L, Mahadik K R, et al. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 2010,1(2): 385.
  • 8International Conference on Harmonization. Stability Testing of New Drug Substances and Products Q1A (R2). IFPMA, Geneva,2003.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部